Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Ob_GLP1

Financiado

Cerrado

Dissecting and leveraging glucagon like peptide 1 brain pathways in obesity

Obesity is a major health challenge in the EU and globally, and yet the best drug therapies achieve only modest reductions in weight loss and require life-long treatment. To prevent and treat obesity it is crucial we understand th... ver más

31/08/2024

UoB

225K€

Presupuesto del proyecto: 225K€

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-08-31

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UoB

224.93K€ | Lider

Proyectos interesantes

TRUSTED

Medical Technol...

Data Science

2M€ Cerrado

SAF2009-11297

Medical Technol...

Data Science

149K€ Cerrado

TRAFALOGY

Medical Technol...

Data Science

193K€ Cerrado

BFU2011-29102

Medical Technol...

Applied Physics

351K€ Cerrado

HEAT-UP

Medical Technol...

Data Science

2M€ Cerrado

FEEDING

Medical Technol...

Data Science

176K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 41 meses Fecha Inicio: 2021-03-13
Fecha Fin: 2024-08-31

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 225K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Obesity is a major health challenge in the EU and globally, and yet the best drug therapies achieve only modest reductions in weight loss and require life-long treatment. To prevent and treat obesity it is crucial we understand the neural pathways controlling appetite and how they can be ‘hijacked’ therapeutically. The brain glucagon-like peptide-1 (GLP1) system is a promising target. GLP1 receptor agonists (GLP1RAs) decrease food intake and bodyweight in obese patients, effects which are mediated by two brain regions: the arcuate nucleus of the hypothalamus (Arc) and the nucleus of the solitary tract (NTS). This project, Ob_GLP1, combines the neuroscience background of Dr Holt with the next-generation technology and imaging expertise of Dr Hodson to test the hypothesis that obesity disrupts the function of GLP1RA-responsive Arc and NTS circuits and that obesity can be rescued by selectively targeting intracellular signalling in GLP1RA-activated neurons. This hypothesis will be tested through the completion of four independent, yet complementary work packages. Work package 1-3 will determine the effect of obesity on 1) GLP1RA access to the Arc and NTS measured using fluorescently labelled GLP1R antagonist and whole-brain light-sheet microscopy; 2) the molecular distribution and oligomerisation state of GLP1Rs in the Arc and NTS; and 3) the innervation pattern and synaptic density of Arc and NTS GLP1R neurons. Work package 4 will assess the potential of a novel GLP1-conjugated antisense nucleotide as an effective anti-obesity treatment. Ob_GLP1 will advance our knowledge of the brain’s control over obesity, while allowing Dr Holt to reintegrate into the European research environment and will facilitate substantial two-way transfer of knowledge between the host lab and Dr Holt, ultimately benefitting both parties, as well as society as a whole.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores